<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB04209</drugbank-id>
  <drugbank-id>EXPT01162</drugbank-id>
  <drugbank-id>DB11615</drugbank-id>
  <name>Dequalinium</name>
  <description>Dequalinium is a quaternary ammonium cation that contains two quaternary quinolinium units linked by an N-decylene chain. It is an antiseptic and disinfectant agent with a broad bactericidal and fungicidal activity. It is most commonly available as a dichloride salt but is available as other various salts as well. It is used in wound dressings and mouth infections and may also have antifungal action, but may associate with skin ulceration. Dequalinium chloride is used as an active ingredient in tablets as Fluomizin for vaginal bacterial infections and in topical bacteriostat formulation as Dequadin. It has been studied for use in treatment of malaria and acute promyelocytic leukemia. Its multiple mode of action is thought to reduce the risk of resistance of pathogens.</description>
  <cas-number>6707-58-0</cas-number>
  <unii>E7QC7V26B8</unii>
  <average-mass>456.6654</average-mass>
  <monoisotopic-mass>456.3252973</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A19280</ref-id>
        <pubmed-id>26506926</pubmed-id>
        <citation>Mendling W, Weissenbacher ER, Gerber S, Prasauskas V, Grob P: Use of locally delivered dequalinium chloride in the treatment of vaginal infections: a review. Arch Gynecol Obstet. 2016 Mar;293(3):469-84. doi: 10.1007/s00404-015-3914-8. Epub 2015 Oct 27.</citation>
      </article>
      <article>
        <ref-id>A19289</ref-id>
        <pubmed-id>26348470</pubmed-id>
        <citation>Timaner M, Bril R, Kaidar-Person O, Rachman-Tzemah C, Alishekevitz D, Kotsofruk R, Miller V, Nevelsky A, Daniel S, Raviv Z, Rotenberg SA, Shaked Y: Dequalinium blocks macrophage-induced metastasis following local radiation. Oncotarget. 2015 Sep 29;6(29):27537-54. doi: 10.18632/oncotarget.4826.</citation>
      </article>
      <article>
        <ref-id>A19290</ref-id>
        <pubmed-id>22875343</pubmed-id>
        <citation>Sancho P, Galeano E, Estan MC, Ganan-Gomez I, Boyano-Adanez Mdel C, Garcia-Perez AI: Raf/MEK/ERK signaling inhibition enhances the ability of dequalinium to induce apoptosis in the human leukemic cell line K562. Exp Biol Med (Maywood). 2012 Aug;237(8):933-42. doi: 10.1258/ebm.2012.011423. Epub 2012 Aug 8.</citation>
      </article>
      <article>
        <ref-id>A19291</ref-id>
        <pubmed-id>21477862</pubmed-id>
        <citation>Garcia-Perez AI, Galeano E, Nieto E, Sancho P: Dequalinium induces human leukemia cell death by affecting the redox balance. Leuk Res. 2011 Oct;35(10):1395-401. doi: 10.1016/j.leukres.2011.03.012. Epub 2011 Apr 8.</citation>
      </article>
      <article>
        <ref-id>A19292</ref-id>
        <pubmed-id>24811390</pubmed-id>
        <citation>Garcia-Perez AI, Galeano E, Nieto E, Estan MC, Sancho P: Dequalinium induces cytotoxicity in human leukemia NB4 cells by downregulation of Raf/MEK/ERK and PI3K/Akt signaling pathways and potentiation of specific inhibitors of these pathways. Leuk Res. 2014 Jul;38(7):795-803. doi: 10.1016/j.leukres.2014.01.009. Epub 2014 Jan 28.</citation>
      </article>
      <article>
        <ref-id>A19293</ref-id>
        <pubmed-id>12404886</pubmed-id>
        <citation>Della Casa V, Noll H, Gonser S, Grob P, Graf F, Pohlig G: Antimicrobial activity of dequalinium chloride against leading germs of vaginal infections. Arzneimittelforschung. 2002;52(9):699-705.</citation>
      </article>
      <article>
        <ref-id>A19294</ref-id>
        <pubmed-id>2483904</pubmed-id>
        <citation>D'Auria FD, Simonetti G, Strippoli V: [Antimicrobial characteristics of a tincture of dequalinium chloride]. Ann Ig. 1989 Sep-Oct;1(5):1227-41.</citation>
      </article>
      <article>
        <ref-id>A19295</ref-id>
        <pubmed-id>3474661</pubmed-id>
        <citation>Weiss MJ, Wong JR, Ha CS, Bleday R, Salem RR, Steele GD Jr, Chen LB: Dequalinium, a topical antimicrobial agent, displays anticarcinoma activity based on selective mitochondrial accumulation. Proc Natl Acad Sci U S A. 1987 Aug;84(15):5444-8.</citation>
      </article>
      <article>
        <ref-id>A19298</ref-id>
        <pubmed-id>19525487</pubmed-id>
        <citation>Gutierrez-Lugo MT, Baker H, Shiloach J, Boshoff H, Bewley CA: Dequalinium, a new inhibitor of Mycobacterium tuberculosis mycothiol ligase identified by high-throughput screening. J Biomol Screen. 2009 Jul;14(6):643-52. doi: 10.1177/1087057109335743. Epub 2009  Jun 12.</citation>
      </article>
      <article>
        <ref-id>A19301</ref-id>
        <pubmed-id>8450414</pubmed-id>
        <citation>Gamboa-Vujicic G, Emma DA, Liao SY, Fuchtner C, Manetta A: Toxicity of the mitochondrial poison dequalinium chloride in a murine model system. J Pharm Sci. 1993 Mar;82(3):231-5.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Effective local treatment as vaginal tablets for infections such as fluor vaginalis, bacterial vaginosis, aerobic vaginitis, vulvo-vaginal candidiasis and trichomoniasis. Used as a topical antimicrobial agent. </indication>
  <pharmacodynamics>Dequalinium is an antimicrobial against Gram negative and positive bacteria, yeast and protozoa. It primarily mediates this action by increasing the cell permeability with subsequent loss of enzyme activity under a rapid bactericidal and fungicidal action. The enzymatic inactivation initially might be reversible but becomes irreversible after a longer contact time between the drug and bacteria [A19280]. The bactericidal and fungicidal effect of dequalinium chloride has been demonstrated to occur within 30–60 min [A19294]. Dequalinium targets a broad spectrum of microorganisms including aerobic and anaerobic bacteria, as well as Candida species. </pharmacodynamics>
  <mechanism-of-action>Dequalinium has a multiple mode of action. It disrupts the cell permeability of the bacteria by absorbing onto the bacterial cell surface and diffusing across the membrane. It also binds to the cytoplasmic membrane with subsequent formation of complexes and protein precipitation and lyses the membrane in adequate concentrations, perturbing osmotic exchange. Loss of normal enzymatic activity is achieved through several different processes. Denaturation of proteins results in inhibition of bacterial cell metabolism. Disruption of bacterial energy production is mediated through inhibition of glucose metabolism and inhibition of mitochondrial ATP synthesis via inhibition of bacterial F1-ATPase. Protein synthesis is also terminated at the level of ribosomes. Bacterial nucleic acids are also affected through direct binding of the drug to DNA in vitro, and precipitation of cytoplasmic material with nucleic acids being the most sensitive [A19280]. &#13;
The cationic form of dequalinium accumulates in the mitochondria and promotes anticancer activity in human leukemia cells. It mediates a cytotoxic effect by altering redox balance in cells and downregulating Raf/MEK/ERK1/2 and PI3K/Akt signaling pathways in these cells which leads to cell death by apoptosis and/or necrosis [A19290, A19291, A19292]. &#13;
Dequalinium inhibits mycothiol ligase activity in Mycobacterium tuberculosis strains [A19298].</mechanism-of-action>
  <toxicity>The oral LD50 value of dequalinium chloride for mouse is 300mg/kg. Lethal dose (LD50) of a single intraperitoneal administration in a murine model system is 18.3 mg/kg. The majority of the adverse reactions of vaginal dequalinium tablets in clinical studies (about 90 %) were local reactions, particularly vaginal discharge, vulvovaginal pruritus, and a vaginal burning sensation. Dequalinuim is not reported to possess embryo-foetal toxicity at clinically relevant doses. </toxicity>
  <metabolism/>
  <absorption>The degree of absorption is minimal in case of topical or vaginal administration thus systemic exposure is negligible. &lt;0.1 % is absorbed systemically after oral administration. </absorption>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as 4-aminoquinolines. These are organic compounds containing an amino group attached to the 4-position of a quinoline ring system.</description>
    <direct-parent>4-aminoquinolines</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organoheterocyclic compounds</superclass>
    <class>Quinolines and derivatives</class>
    <subclass>Aminoquinolines and derivatives</subclass>
    <alternative-parent>Aminopyridines and derivatives</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Benzenoids</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Methylpyridines</alternative-parent>
    <alternative-parent>Organic cations</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Primary amines</alternative-parent>
    <alternative-parent>Pyridinium derivatives</alternative-parent>
    <substituent>4-aminoquinoline</substituent>
    <substituent>Amine</substituent>
    <substituent>Aminopyridine</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Methylpyridine</substituent>
    <substituent>Organic cation</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Primary amine</substituent>
    <substituent>Pyridine</substituent>
    <substituent>Pyridinium</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT002402</drugbank-id>
      <name>Dequalinium acetate</name>
      <unii>P8W4UX112S</unii>
      <cas-number>4028-98-2</cas-number>
      <inchikey/>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT002400</drugbank-id>
      <name>Dequalinium bromide</name>
      <unii/>
      <cas-number/>
      <inchikey/>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT001926</drugbank-id>
      <name>Dequalinium chloride</name>
      <unii>XYS8INN1I6</unii>
      <cas-number>522-51-0</cas-number>
      <inchikey>LTNZEXKYNRNOGT-UHFFFAOYSA-N</inchikey>
      <average-mass>527.58</average-mass>
      <monoisotopic-mass>526.2630027</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT002401</drugbank-id>
      <name>Dequalinium iodide</name>
      <unii/>
      <cas-number/>
      <inchikey/>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT002403</drugbank-id>
      <name>Dequalinium undecenoate</name>
      <unii/>
      <cas-number/>
      <inchikey/>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">1,1'-(1,10-Decanediyl)bis(4-amino-2-methylquinolinium) dichloride</synonym>
    <synonym language="english" coder="">1,1'-Decamethylenebis(4-aminoquinaldinium chloride)</synonym>
    <synonym language="english" coder="">Decamethylenebis(4-aminoquinaldinium chloride)</synonym>
  </synonyms>
  <products>
    <product>
      <name>Dequadin</name>
      <labeller>Boyd Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02100207</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dequadin Mint Loz 0.25mg</name>
      <labeller>Glaxo Canada Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00110566</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-12-31</started-marketing-on>
      <ended-marketing-on>1998-07-30</ended-marketing-on>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dequadin Oral Paint</name>
      <labeller>Boyd Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02091453</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Buccal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dequadin Oral Paint .5%</name>
      <labeller>Glaxo Canada Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00110574</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1958-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-10</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Dequadin Oral Paint .5%</name>
      <ingredients>Dequalinium</ingredients>
    </mixture>
    <mixture>
      <name>Dequadin Mint Loz 0.25mg</name>
      <ingredients>Dequalinium</ingredients>
    </mixture>
    <mixture>
      <name>Dequadin Oral Paint</name>
      <ingredients>Dequalinium</ingredients>
    </mixture>
    <mixture>
      <name>Dequadin</name>
      <ingredients>Dequalinium</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents, Local</category>
      <mesh-id>D000891</mesh-id>
    </category>
    <category>
      <category>Antiseptics and Disinfectants</category>
      <mesh-id/>
    </category>
    <category>
      <category>Dermatologicals</category>
      <mesh-id>D003879</mesh-id>
    </category>
    <category>
      <category>Genito Urinary System and Sex Hormones</category>
      <mesh-id/>
    </category>
    <category>
      <category>Gynecological Antiinfectives and Antiseptics</category>
      <mesh-id/>
    </category>
    <category>
      <category>Heterocyclic Compounds, Fused-Ring</category>
      <mesh-id>D000072471</mesh-id>
    </category>
    <category>
      <category>Miscellaneous Anti-infectives</category>
      <mesh-id/>
    </category>
    <category>
      <category>Quinoline Derivatives</category>
      <mesh-id/>
    </category>
    <category>
      <category>Quinolines</category>
      <mesh-id>D011804</mesh-id>
    </category>
    <category>
      <category>Quinolinium Compounds</category>
      <mesh-id>D011806</mesh-id>
    </category>
    <category>
      <category>Throat Preparations</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Candida albicans and other yeasts</affected-organism>
    <affected-organism>Trichomonas vaginalis, Giardia duodenalis, and Entamoeba histolytica</affected-organism>
    <affected-organism>Bacteria and protozoa</affected-organism>
    <affected-organism>Bacteroides</affected-organism>
    <affected-organism>Peptostreptococcus</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Lozenge</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Buccal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Oral</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="D08AH01">
      <level code="D08AH">Quinoline derivatives</level>
      <level code="D08A">ANTISEPTICS AND DISINFECTANTS</level>
      <level code="D08">ANTISEPTICS AND DISINFECTANTS</level>
      <level code="D">DERMATOLOGICALS</level>
    </atc-code>
    <atc-code code="R02AA02">
      <level code="R02AA">Antiseptics</level>
      <level code="R02A">THROAT PREPARATIONS</level>
      <level code="R02">THROAT PREPARATIONS</level>
      <level code="R">RESPIRATORY SYSTEM</level>
    </atc-code>
    <atc-code code="G01AC05">
      <level code="G01AC">Quinoline derivatives</level>
      <level code="G01A">ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS</level>
      <level code="G01">GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>52:04.92</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>1jt6</pdb-entry>
    <pdb-entry>1oyd</pdb-entry>
    <pdb-entry>3arp</pdb-entry>
    <pdb-entry>3art</pdb-entry>
    <pdb-entry>3br1</pdb-entry>
    <pdb-entry>3br2</pdb-entry>
    <pdb-entry>3bt9</pdb-entry>
    <pdb-entry>3btj</pdb-entry>
    <pdb-entry>3vw0</pdb-entry>
  </pdb-entries>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB04209.pdf?1495663129</msds>
  <patents>
    <patent>
      <number>4946849</number>
      <country>United States</country>
      <approved>1990-08-07</approved>
      <expires>2002-10-01</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>0.16</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-9</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>4.77e-07 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-3.6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>4-amino-1-[10-(4-amino-2-methylquinolin-1-ium-1-yl)decyl]-2-methylquinolin-1-ium</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>dequadin</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>456.6654</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>456.3252973</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CC1=CC(N)=C2C=CC=CC2=[N+]1CCCCCCCCCC[N+]1=C(C)C=C(N)C2=C1C=CC=C2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C30H40N4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C30H38N4/c1-23-21-27(31)25-15-9-11-17-29(25)33(23)19-13-7-5-3-4-6-8-14-20-34-24(2)22-28(32)26-16-10-12-18-30(26)34/h9-12,15-18,21-22,31-32H,3-8,13-14,19-20H2,1-2H3/p+2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>PCSWXVJAIHCTMO-UHFFFAOYSA-P</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>59.8</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>147</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>56.76</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>11</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-0.34</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>Decomposes at 326ºC</value>
      <source>MSDS</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>5913</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>41872</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>2993</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46507206</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>2886</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50048403</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>DEQ</identifier>
    </external-identifier>
    <external-identifier>
      <resource>IUPHAR</resource>
      <identifier>2313</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Guide to Pharmacology</resource>
      <identifier>2313</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Dequalinium</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL333826</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>Drugs.com</resource>
      <url>https://www.drugs.com/international/dequalinium-chloride.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0001817</id>
      <name>Acriflavine resistance protein B</name>
      <organism>Escherichia coli (strain K12)</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P31224" source="Swiss-Prot">
        <name>Multidrug efflux pump subunit AcrB</name>
        <general-function>Identical protein binding</general-function>
        <specific-function>AcrA-AcrB-AcrZ-TolC is a drug efflux protein complex with broad substrate specificity that uses the proton motive force to export substrates.Involved in contact-dependent growth inhibition (CDI), acts downstream of BamA, the receptor for CDI. Its role in CDI is independent of the AcrA-AcrB-TolC efflux pump complex.</specific-function>
        <gene-name>acrB</gene-name>
        <locus/>
        <cellular-location>Cell inner membrane</cellular-location>
        <transmembrane-regions>10-28
337-356
366-385
392-413
439-457
466-490
539-555
872-888
899-918
925-943
973-992
999-1018</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>5.23</theoretical-pi>
        <molecular-weight>113572.75</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="83333">Escherichia coli (strain K12)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M94248</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>290406</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P31224</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ACRB_ECOLI</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>AcrAB-TolC multidrug efflux pump subunit AcrB</synonym>
          <synonym>acrE</synonym>
          <synonym>Acridine resistance protein B</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016571|Multidrug efflux pump subunit AcrB
MPNFFIDRPIFAWVIAIIIMLAGGLAILKLPVAQYPTIAPPAVTISASYPGADAKTVQDT
VTQVIEQNMNGIDNLMYMSSNSDSTGTVQITLTFESGTDADIAQVQVQNKLQLAMPLLPQ
EVQQQGVSVEKSSSSFLMVVGVINTDGTMTQEDISDYVAANMKDAISRTSGVGDVQLFGS
QYAMRIWMNPNELNKFQLTPVDVITAIKAQNAQVAAGQLGGTPPVKGQQLNASIIAQTRL
TSTEEFGKILLKVNQDGSRVLLRDVAKIELGGENYDIIAEFNGQPASGLGIKLATGANAL
DTAAAIRAELAKMEPFFPSGLKIVYPYDTTPFVKISIHEVVKTLVEAIILVFLVMYLFLQ
NFRATLIPTIAVPVVLLGTFAVLAAFGFSINTLTMFGMVLAIGLLVDDAIVVVENVERVM
AEEGLPPKEATRKSMGQIQGALVGIAMVLSAVFVPMAFFGGSTGAIYRQFSITIVSAMAL
SVLVALILTPALCATMLKPIAKGDHGEGKKGFFGWFNRMFEKSTHHYTDSVGGILRSTGR
YLVLYLIIVVGMAYLFVRLPSSFLPDEDQGVFMTMVQLPAGATQERTQKVLNEVTHYYLT
KEKNNVESVFAVNGFGFAGRGQNTGIAFVSLKDWADRPGEENKVEAITMRATRAFSQIKD
AMVFAFNLPAIVELGTATGFDFELIDQAGLGHEKLTQARNQLLAEAAKHPDMLTSVRPNG
LEDTPQFKIDIDQEKAQALGVSINDINTTLGAAWGGSYVNDFIDRGRVKKVYVMSEAKYR
MLPDDIGDWYVRAADGQMVPFSAFSSSRWEYGSPRLERYNGLPSMEILGQAAPGKSTGEA
MELMEQLASKLPTGVGYDWTGMSYQERLSGNQAPSLYAISLIVVFLCLAALYESWSIPFS
VMLVVPLGVIGALLAATFRGLTNDVYFQVGLLTTIGLSAKNAILIVEFAKDLMDKEGKGL
IEATLDAVRMRLRPILMTSLAFILGVMPLVISTGAGSGAQNAVGTGVMGGMVTATVLAIF
FVPVFFVVVRRRFSRKNEDIEHSHTVDHH</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016572|Multidrug efflux pump subunit AcrB (acrB)
ATGCCTAATTTCTTTATCGATCGCCCGATTTTTGCGTGGGTGATCGCCATTATCATCATG
TTGGCAGGGGGGCTGGCGATCCTCAAACTGCCGGTGGCGCAATATCCTACGATTGCACCG
CCGGCAGTAACGATCTCCGCCTCCTACCCCGGCGCTGATGCGAAAACAGTGCAGGACACG
GTGACACAGGTTATCGAACAGAATATGAACGGTATCGATAACCTGATGTACATGTCCTCT
AACAGTGACTCCACGGGTACCGTGCAGATCACCCTGACCTTTGAGTCTGGTACTGATGCG
GATATCGCGCAGGTTCAGGTGCAGAACAAACTGCAGCTGGCGATGCCGTTGCTGCCGCAA
GAAGTTCAGCAGCAAGGGGTGAGCGTTGAGAAATCATCCAGCAGCTTCCTGATGGTTGTC
GGCGTTATCAACACCGATGGCACCATGACGCAGGAGGATATCTCCGACTACGTGGCGGCG
AATATGAAAGATGCCATCAGCCGTACGTCGGGCGTGGGTGATGTTCAGTTGTTCGGTTCA
CAGTACGCGATGCGTATCTGGATGAACCCGAATGAGCTGAACAAATTCCAGCTAACGCCG
GTTGATGTCATTACCGCCATCAAAGCGCAGAACGCCCAGGTTGCGGCGGGTCAGCTCGGT
GGTACGCCGCCGGTGAAAGGCCAACAGCTTAACGCCTCTATTATTGCTCAGACGCGTCTG
ACCTCTACTGAAGAGTTCGGCAAAATCCTGCTGAAAGTGAATCAGGATGGTTCCCGCGTG
CTGCTGCGTGACGTCGCGAAGATTGAGCTGGGTGGTGAGAACTACGACATCATCGCAGAG
TTTAACGGCCAACCGGCTTCCGGTCTGGGGATCAAGCTGGCGACCGGTGCAAACGCGCTG
GATACCGCTGCGGCAATCCGTGCTGAACTGGCGAAGATGGAACCGTTCTTCCCGTCGGGT
CTGAAAATTGTTTACCCATACGACACCACGCCGTTCGTGAAAATCTCTATTCACGAAGTG
GTTAAAACGCTGGTCGAAGCGATCATCCTCGTGTTCCTGGTTATGTATCTGTTCCTGCAG
AACTTCCGCGCGACGTTGATTCCGACCATTGCCGTACCGGTGGTATTGCTCGGGACCTTT
GCCGTCCTTGCCGCCTTTGGCTTCTCGATAAACACGCTAACAATGTTCGGGATGGTGCTC
GCCATCGGCCTGTTGGTGGATGACGCCATCGTTGTGGTAGAAAACGTTGAGCGTGTTATG
GCGGAAGAAGGTTTGCCGCCAAAAGAAGCTACCCGTAAGTCGATGGGGCAGATTCAGGGC
GCTCTGGTCGGTATCGCGATGGTACTGTCGGCGGTATTCGTACCGATGGCCTTCTTTGGC
GGTTCTACTGGTGCTATCTATCGTCAGTTCTCTATTACCATTGTTTCAGCAATGGCGCTG
TCGGTACTGGTGGCGTTGATCCTGACTCCAGCTCTTTGTGCCACCATGCTGAAACCGATT
GCCAAAGGCGATCACGGGGAAGGTAAAAAAGGCTTCTTCGGCTGGTTTAACCGCATGTTC
GAGAAGAGCACGCACCACTACACCGACAGCGTAGGCGGTATTCTGCGCAGTACGGGGCGT
TACCTGGTGCTGTATCTGATCATCGTGGTCGGCATGGCCTATCTGTTCGTGCGTCTGCCA
AGCTCCTTCTTGCCAGATGAGGACCAGGGCGTGTTTATGACCATGGTTCAGCTGCCAGCA
GGTGCAACGCAGGAACGTACACAGAAAGTGCTCAATGAGGTAACGCATTACTATCTGACC
AAAGAAAAGAACAACGTTGAGTCGGTGTTCGCCGTTAACGGCTTCGGCTTTGCGGGACGT
GGTCAGAATACCGGTATTGCGTTCGTTTCCTTGAAGGACTGGGCCGATCGTCCGGGCGAA
GAAAACAAAGTTGAAGCGATTACCATGCGTGCAACACGCGCTTTCTCGCAAATCAAAGAT
GCGATGGTTTTCGCCTTTAACCTGCCCGCAATCGTGGAACTGGGTACTGCAACCGGCTTT
GACTTTGAGCTGATTGACCAGGCTGGCCTTGGTCACGAAAAACTGACTCAGGCGCGTAAC
CAGTTGCTTGCAGAAGCAGCGAAGCACCCTGATATGTTGACCAGCGTACGTCCAAACGGT
CTGGAAGATACCCCGCAGTTTAAGATTGATATCGACCAGGAAAAAGCGCAGGCGCTGGGT
GTTTCTATCAACGACATTAACACCACTCTGGGCGCTGCATGGGGCGGCAGCTATGTGAAC
GACTTTATCGACCGCGGTCGTGTGAAGAAAGTTTATGTCATGTCAGAAGCGAAATACCGT
ATGCTGCCGGATGATATCGGCGACTGGTATGTTCGTGCTGCTGATGGTCAGATGGTGCCA
TTCTCGGCGTTCTCCTCTTCTCGTTGGGAGTACGGTTCGCCGCGTCTGGAACGTTACAAC
GGCCTGCCATCCATGGAAATCTTAGGCCAGGCGGCACCGGGTAAAAGTACCGGTGAAGCA
ATGGAGCTGATGGAACAACTGGCGAGCAAACTGCCTACCGGTGTTGGCTATGACTGGACG
GGGATGTCCTATCAGGAACGTCTCTCCGGCAACCAGGCACCTTCACTGTACGCGATTTCG
TTGATTGTCGTGTTCCTGTGTCTGGCGGCGCTGTACGAGAGCTGGTCGATTCCGTTCTCC
GTTATGCTGGTCGTTCCGCTGGGGGTTATCGGTGCGTTGCTGGCTGCCACCTTCCGTGGC
CTGACCAATGACGTTTACTTCCAGGTAGGCCTGCTCACAACCATTGGGTTGTCGGCGAAG
AACGCGATCCTTATCGTCGAATTCGCCAAAGACTTGATGGATAAAGAAGGTAAAGGTCTG
ATTGAAGCGACGCTTGATGCGGTGCGGATGCGTTTACGTCCGATCCTGATGACCTCGCTG
GCGTTTATCCTCGGCGTTATGCCGCTGGTTATCAGTACTGGTGCTGGTTCCGGCGCGCAG
AACGCAGTAGGTACCGGTGTAATGGGCGGGATGGTGACCGCAACGGTACTGGCAATCTTC
TTCGTTCCGGTATTCTTTGTGGTGGTTCGCCGCCGCTTTAGCCGCAAGAATGAAGATATC
GAGCACAGCCATACTGTCGATCATCATTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00873</identifier>
            <name>ACR_tran</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>identical protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug export</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target>
      <id>BE0001268</id>
      <name>HTH-type transcriptional regulator QacR</name>
      <organism>Staphylococcus haemolyticus</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P0A0N5" source="Swiss-Prot">
        <name>HTH-type transcriptional regulator QacR</name>
        <general-function>Transcription factor activity, sequence-specific dna binding</general-function>
        <specific-function>Transcriptional repressor of qacA. Binds to IR1, an unusually long 28 bp operator, which is located downstream from the qacA promoter and overlaps its transcription start site. QacR is induced from its IR1 site by binding to one of many structurally dissimilar cationic lipophilic compounds, which are also substrates of QacA (By similarity).</specific-function>
        <gene-name>qacR</gene-name>
        <locus/>
        <cellular-location>Cytoplasmic</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.55</theoretical-pi>
        <molecular-weight>22174.175</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="1283">Staphylococcus haemolyticus</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AJ400722</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>8574416</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P0A0N5</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>QACR_STAHA</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms/>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010884|HTH-type transcriptional regulator QacR
MNLKDKILGVAKELFIKNGYNATTTGEIVKLSESSKGNLYYHFKTKENLFLEILNIEESK
WQEQWKKEQIKCKTNREKFYLYNELSLTTEYYYPLQNAIIEFYTEYYKTNSINEKMNKLE
NKYIDAYHVIFKEGNLNGEWCINDVNAVSKIAANAVNGIVTFTHEQNINERIKLMNKFSQ
IFLNGLSK</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0002522|567 bp
TTATTTACTAAGTCCATTTAAAAAAATTTGAGAGAACTTGTTCATAAGTTTAATTCTTTC
ATTAATATTTTGTTCATGTGTAAAGGTAACAATTCCATTAACAGCGTTTGCTGCTATTTT
ACTAACAGCATTAACATCATTAATACACCATTCGCCATTTAAATTACCCTCCTTAAAAAT
TACATGATAAGCATCTATATATTTGTTTTCTAATTTATTCATTTTTTCATTAATGCTATT
AGTTTTATAATATTCAGTGTAAAATTCAATTATTGCGTTTTGAAGTGGATAATAGTATTC
GGTTGTTAAAGATAGTTCATTATATAAATAAAATTTTTCTCTATTAGTTTTACATTTGAT
TTGTTCCTTTTTCCACTGTTCTTGCCATTTAGATTCTTCTATATTTAAAATTTCTAAAAA
TAGATTTTCTTTTGTTTTAAAGTGATAATAAAGATTCCCTTTACTACTTTCTGATAATTT
AACAATTTCTCCAGTAGTAGTGGCATTATATCCATTTTTTATAAATAATTCCTTTGCGAC
ACCTAGTATTTTATCTTTCAAGTTCAT</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF08360</identifier>
            <name>TetR_C_5</name>
          </pfam>
          <pfam>
            <identifier>PF00440</identifier>
            <name>TetR_N</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription factor activity, sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription, DNA-templated</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="1">
      <id>BE0001156</id>
      <name>E3 ubiquitin-protein ligase XIAP</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A19296</ref-id>
            <pubmed-id>21340509</pubmed-id>
            <citation>Orzaez M, Gortat A, Sancho M, Carbajo RJ, Pineda-Lucena A, Palacios-Rodriguez Y, Perez-Paya E: Characterization of dequalinium as a XIAP antagonist that targets the BIR2 domain. Apoptosis. 2011 May;16(5):460-7. doi: 10.1007/s10495-011-0582-4.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P98170" source="Swiss-Prot">
        <name>E3 ubiquitin-protein ligase XIAP</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, copper homeostasis, mitogenic kinase signaling, cell proliferation, as well as cell invasion and metastasis. Acts as a direct caspase inhibitor. Directly bind to the active site pocket of CASP3 and CASP7 and obstructs substrate entry. Inactivates CASP9 by keeping it in a monomeric, inactive state. Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and the target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, CASP3, CASP7, CASP8, CASP9, MAP3K2/MEKK2, DIABLO/SMAC, AIFM1, CCS and BIRC5/survivin. Ubiquitinion of CCS leads to enhancement of its chaperone activity toward its physiologic target, SOD1, rather than proteasomal degradation. Ubiquitinion of MAP3K2/MEKK2 and AIFM1 does not lead to proteasomal degradation. Plays a role in copper homeostasis by ubiquitinationg COMMD1 and promoting its proteasomal degradation. Can also function as E3 ubiquitin-protein ligase of the NEDD8 conjugation pathway, targeting effector caspases for neddylation and inactivation. Regulates the BMP signaling pathway and the SMAD and MAP3K7/TAK1 dependent pathways leading to NF-kappa-B and JNK activation. Acts as an important regulator of innate immune signaling via regulation of Nodlike receptors (NLRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase-independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8. Acts as a positive regulator of Wnt signaling and ubiquitinates TLE1, TLE2, TLE3, TLE4 and AES. Ubiquitination of TLE3 results in inhibition of its interaction with TCF7L2/TCF4 thereby allowing efficient recruitment and binding of the transcriptional coactivator beta-catenin to TCF7L2/TCF4 that is required to initiate a Wnt-specific transcriptional program.</specific-function>
        <gene-name>XIAP</gene-name>
        <locus>Xq25</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.63</theoretical-pi>
        <molecular-weight>56684.41</molecular-weight>
        <chromosome-location>X</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:592</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>BIRC4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U45880</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1184320</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2790</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P98170</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>XIAP_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>6.3.2.-</synonym>
          <synonym>API3</synonym>
          <synonym>Baculoviral IAP repeat-containing protein 4</synonym>
          <synonym>BIRC4</synonym>
          <synonym>hIAP-3</synonym>
          <synonym>hIAP3</synonym>
          <synonym>hILP</synonym>
          <synonym>IAP-3</synonym>
          <synonym>IAP-like protein</synonym>
          <synonym>IAP3</synonym>
          <synonym>ILP</synonym>
          <synonym>Inhibitor of apoptosis protein 3</synonym>
          <synonym>X-linked IAP</synonym>
          <synonym>X-linked inhibitor of apoptosis protein</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010806|E3 ubiquitin-protein ligase XIAP
MTFNSFEGSKTCVPADINKEEEFVEEFNRLKTFANFPSGSPVSASTLARAGFLYTGEGDT
VRCFSCHAAVDRWQYGDSAVGRHRKVSPNCRFINGFYLENSATQSTNSGIQNGQYKVENY
LGSRDHFALDRPSETHADYLLRTGQVVDISDTIYPRNPAMYSEEARLKSFQNWPDYAHLT
PRELASAGLYYTGIGDQVQCFCCGGKLKNWEPCDRAWSEHRRHFPNCFFVLGRNLNIRSE
SDAVSSDRNFPNSTNLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYALGEGDKVKC
FHCGGGLTDWKPSEDPWEQHAKWYPGCKYLLEQKGQEYINNIHLTHSLEECLVRTTEKTP
SLTRRIDDTIFQNPMVQEAIRMGFSFKDIKKIMEEKIQISGSNYKSLEVLVADLVNAQKD
SMQDESSQTSLQKEISTEEQLRRLQEEKLCKICMDRNIAIVFVPCGHLVTCKQCAEAVDK
CPMCYTVITFKQKIFMS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010807|E3 ubiquitin-protein ligase XIAP (XIAP)
ATGACTTTTAACAGTTTTGAAGGATCTAAAACTTGTGTACCTGCAGACATCAATAAGGAA
GAAGAATTTGTAGAAGAGTTTAATAGATTAAAAACTTTTGCTAATTTTCCAAGTGGTAGT
CCTGTTTCAGCATCAACACTGGCACGAGCAGGGTTTCTTTATACTGGTGAAGGAGATACC
GTGCGGTGCTTTAGTTGTCATGCAGCTGTAGATAGATGGCAATATGGAGACTCAGCAGTT
GGAAGACACAGGAAAGTATCCCCAAATTGCAGATTTATCAACGGCTTTTATCTTGAAAAT
AGTGCCACGCAGTCTACAAATTCTGGTATCCAGAATGGTCAGTACAAAGTTGAAAACTAT
CTGGGAAGCAGAGATCATTTTGCCTTAGACAGGCCATCTGAGACACATGCAGACTATCTT
TTGAGAACTGGGCAGGTTGTAGATATATCAGACACCATATACCCGAGGAACCCTGCCATG
TATAGTGAAGAAGCTAGATTAAAGTCCTTTCAGAACTGGCCAGACTATGCTCACCTAACC
CCAAGAGAGTTAGCAAGTGCTGGACTCTACTACACAGGTATTGGTGACCAAGTGCAGTGC
TTTTGTTGTGGTGGAAAACTGAAAAATTGGGAACCTTGTGATCGTGCCTGGTCAGAACAC
AGGCGACACTTTCCTAATTGCTTCTTTGTTTTGGGCCGGAATCTTAATATTCGAAGTGAA
TCTGATGCTGTGAGTTCTGATAGGAATTTCCCAAATTCAACAAATCTTCCAAGAAATCCA
TCCATGGCAGATTATGAAGCACGGATCTTTACTTTTGGGACATGGATATACTCAGTTAAC
AAGGAGCAGCTTGCAAGAGCTGGATTTTATGCTTTAGGTGAAGGTGATAAAGTAAAGTGC
TTTCACTGTGGAGGAGGGCTAACTGATTGGAAGCCCAGTGAAGACCCTTGGGAACAACAT
GCTAAATGGTATCCAGGGTGCAAATATCTGTTAGAACAGAAGGGACAAGAATATATAAAC
AATATTCATTTAACTCATTCACTTGAGGAGTGTCTGGTAAGAACTACTGAGAAAACACCA
TCACTAACTAGAAGAATTGATGATACCATCTTCCAAAATCCTATGGTACAAGAAGCTATA
CGAATGGGGTTCAGTTTCAAGGACATTAAGAAAATAATGGAGGAAAAAATTCAGATATCT
GGGAGCAACTATAAATCACTTGAGGTTCTGGTTGCAGATCTAGTGAATGCTCAGAAAGAC
AGTATGCAAGATGAGTCAAGTCAGACTTCATTACAGAAAGAGATTAGTACTGAAGAGCAG
CTAAGGCGCCTGCAAGAGGAGAAGCTTTGCAAAATCTGTATGGATAGAAATATTGCTATC
GTTTTTGTTCCTTGTGGACATCTAGTCACTTGTAAACAATGTGCTGAAGCAGTTGACAAG
TGTCCCATGTGCTACACAGTCATTACTTTCAAGCAAAAAATTTTTATGTCTTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00653</identifier>
            <name>BIR</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cysteine-type endopeptidase inhibitor activity involved in apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ligase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ubiquitin protein ligase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ubiquitin-protein transferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to DNA damage stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>copper ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inhibition of cysteine-type endopeptidase activity involved in apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intrinsic apoptotic signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cysteine-type endopeptidase activity involved in apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of canonical Wnt signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein linear polyubiquitination</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein ubiquitination</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>programmed cell death</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein ubiquitination</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of BMP signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of nucleotide-binding oligomerization domain containing signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Wnt signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0005300</id>
      <name>cGMP-gated cation channel alpha-1</name>
      <organism>Humans</organism>
      <actions>
        <action>blocker</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A19297</ref-id>
            <pubmed-id>12508052</pubmed-id>
            <citation>Rosenbaum T, Islas LD, Carlson AE, Gordon SE: Dequalinium: a novel, high-affinity blocker of CNGA1 channels. J Gen Physiol. 2003 Jan;121(1):37-47.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P29973" source="Swiss-Prot">
        <name>cGMP-gated cation channel alpha-1</name>
        <general-function>Voltage-gated potassium channel activity</general-function>
        <specific-function>Visual signal transduction is mediated by a G-protein coupled cascade using cGMP as second messenger. This protein can be activated by cyclic GMP which leads to an opening of the cation channel and thereby causing a depolarization of rod photoreceptors.</specific-function>
        <gene-name>CNGA1</gene-name>
        <locus/>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>165-185
199-217
242-261
300-322
375-394
479-499</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>79584.825</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2148</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>394</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P29973</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CNGA1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>CNCG</synonym>
          <synonym>CNCG1</synonym>
          <synonym>CNG channel alpha-1</synonym>
          <synonym>CNG-1</synonym>
          <synonym>CNG1</synonym>
          <synonym>Cyclic nucleotide-gated cation channel 1</synonym>
          <synonym>Cyclic nucleotide-gated channel alpha-1</synonym>
          <synonym>Cyclic nucleotide-gated channel, photoreceptor</synonym>
          <synonym>Rod photoreceptor cGMP-gated channel subunit alpha</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0009062|cGMP-gated cation channel alpha-1
MKLSMKNNIINTQQSFVTMPNVIVPDIEKEIRRMENGACSSFSEDDDSASTSEESENENP
HARGSFSYKSLRKGGPSQREQYLPGAIALFNVNNSSNKDQEPEEKKKKKKEKKSKSDDKN
ENKNDPEKKKKKKDKEKKKKEEKSKDKKEEEKKEVVVIDPSGNTYYNWLFCITLPVMYNW
TMVIARACFDELQSDYLEYWLILDYVSDIVYLIDMFVRTRTGYLEQGLLVKEELKLINKY
KSNLQFKLDVLSLIPTDLLYFKLGWNYPEIRLNRLLRFSRMFEFFQRTETRTNYPNIFRI
SNLVMYIVIIIHWNACVFYSISKAIGFGNDTWVYPDINDPEFGRLARKYVYSLYWSTLTL
TTIGETPPPVRDSEYVFVVVDFLIGVLIFATIVGNIGSMISNMNAARAEFQARIDAIKQY
MHFRNVSKDMEKRVIKWFDYLWTNKKTVDEKEVLKYLPDKLRAEIAINVHLDTLKKVRIF
ADCEAGLLVELVLKLQPQVYSPGDYICKKGDIGREMYIIKEGKLAVVADDGVTQFVVLSD
GSYFGEISILNIKGSKAGNRRTANIKSIGYSDLFCLSKDDLMEALTEYPDAKTMLEEKGK
QILMKDGLLDLNIANAGSDPKDLEEKVTRMEGSVDLLQTRFARILAEYESMQQKLKQRLT
KVEKFLKPLIDTEFSSIEGPGAESGPIDST</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019714|cGMP-gated cation channel alpha-1 (CNGA1)
ATGAAACTATCCATGAAGAACAATATTATCAATACACAGCAGTCTTTTGTAACCATGCCC
AATGTGATTGTACCAGATATTGAAAAGGAAATACGAAGGATGGAAAATGGAGCATGCAGC
TCCTTTTCTGAGGATGATGACAGTGCCTCTACATCTGAAGAATCAGAGAATGAAAACCCT
CATGCAAGGGGTTCCTTTAGTTATAAGTCACTCAGAAAGGGAGGACCATCACAGAGGGAG
CAGTACCTGCCTGGTGCCATTGCACTTTTTAATGTGAACAACAGCAGCAATAAGGACCAG
GAACCAGAAGAAAAAAAGAAAAAGAAAAAAGAAAAGAAGAGCAAGTCAGATGATAAAAAC
GAAAATAAAAACGACCCAGAGAAGAAAAAGAAGAAAAAGGACAAAGAGAAGAAAAAGAAA
GAGGAGAAAAGCAAAGATAAGAAAGAAGAGGAGAAGAAAGAAGTTGTGGTTATTGATCCC
TCGGGAAACACATATTACAACTGGCTGTTTTGCATCACATTACCTGTTATGTACAACTGG
ACAATGGTTATTGCCAGAGCATGTTTTGATGAACTTCAATCTGATTACCTAGAATATTGG
CTCATTTTGGATTACGTATCAGACATAGTCTATTTAATCGATATGTTTGTACGAACAAGG
ACAGGTTACCTAGAACAAGGACTGCTGGTAAAGGAAGAACTTAAACTCATAAATAAATAT
AAATCCAACTTGCAATTTAAACTTGATGTTCTGTCACTGATACCAACTGATTTGCTGTAT
TTTAAGTTAGGGTGGAACTATCCAGAAATTAGATTAAACAGGTTGTTACGGTTCTCTCGT
ATGTTTGAGTTCTTCCAGAGAACAGAAACAAGGACAAACTATCCAAACATCTTCAGGATT
TCCAACCTTGTTATGTATATCGTCATCATTATCCACTGGAATGCATGTGTGTTCTACTCT
ATTTCTAAAGCTATTGGATTTGGAAATGATACATGGGTCTACCCTGATATTAATGATCCT
GAATTTGGCCGTTTGGCTAGAAAATACGTATACAGCCTTTACTGGTCTACACTGACTTTG
ACTACCATTGGTGAAACACCCCCTCCCGTGAGGGATTCTGAGTATGTCTTTGTGGTGGTT
GATTTCCTAATTGGAGTGTTAATTTTTGCTACCATCGTTGGTAACATAGGTTCTATGATT
TCCAACATGAATGCAGCCAGAGCAGAATTTCAAGCAAGAATTGATGCTATCAAGCAATAT
ATGCATTTTCGAAATGTAAGCAAAGATATGGAAAAGAGGGTTATTAAATGGTTTGACTAC
CTGTGGACCAACAAAAAAACAGTTGATGAGAAAGAAGTCTTAAAGTATCTACCTGATAAA
CTAAGAGCAGAAATTGCCATCAACGTTCACTTAGACACATTAAAAAAGGTACGCATTTTT
GCTGATTGTGAAGCTGGTCTGTTGGTGGAGTTGGTCTTGAAATTGCAACCCCAAGTCTAC
AGTCCTGGAGATTATATTTGCAAGAAAGGGGATATCGGACGAGAGATGTACATTATCAAG
GAAGGCAAACTCGCTGTGGTGGCAGATGATGGAGTCACTCAGTTTGTGGTATTGAGCGAT
GGCAGCTACTTCGGTGAGATCAGCATTCTTAACATTAAAGGGAGCAAAGCTGGCAATCGA
AGAACGGCCAATATTAAAAGTATTGGCTACTCAGACCTGTTCTGTCTCTCAAAAGATGAC
CTCATGGAAGCTCTAACTGAGTACCCAGATGCCAAAACTATGCTGGAAGAGAAAGGGAAG
CAGATTTTAATGAAAGATGGTCTACTGGATCTAAACATTGCAAATGCTGGCAGTGATCCT
AAAGATCTTGAAGAGAAGGTTACTCGAATGGAGGGGTCAGTAGACCTCCTGCAAACCAGG
TTTGCCCGAATCTTGGCTGAGTATGAGTCCATGCAGCAGAAACTGAAACAAAGATTAACC
AAGGTTGAGAAATTTCTGAAACCGCTTATTGACACAGAATTTTCAAGTATTGAGGGACCT
GGAGCGGAAAGTGGGCCCATCGACTCTACATAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00520</identifier>
            <name>Ion_trans</name>
          </pfam>
          <pfam>
            <identifier>PF00027</identifier>
            <name>cNMP_binding</name>
          </pfam>
          <pfam>
            <identifier>PF16526</identifier>
            <name>CLZ</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>photoreceptor outer segment membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cGMP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>intracellular cAMP activated cation channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>intracellular cGMP activated cation channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated potassium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phototransduction, visible light</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>potassium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of rhodopsin mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>rhodopsin mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>visual perception</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="3">
      <id>BE0000553</id>
      <name>Calcium-activated potassium channel subunit alpha-1</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A19299</ref-id>
            <pubmed-id>8100530</pubmed-id>
            <citation>Castle NA, Haylett DG, Morgan JM, Jenkinson DH: Dequalinium: a potent inhibitor of apamin-sensitive K+ channels in hepatocytes and of nicotinic responses in skeletal muscle. Eur J Pharmacol. 1993 May 19;236(2):201-7.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q12791" source="Swiss-Prot">
        <name>Calcium-activated potassium channel subunit alpha-1</name>
        <general-function>Voltage-gated potassium channel activity</general-function>
        <specific-function>Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+). It is also activated by the concentration of cytosolic Mg(2+). Its activation dampens the excitatory events that elevate the cytosolic Ca(2+) concentration and/or depolarize the cell membrane. It therefore contributes to repolarization of the membrane potential. Plays a key role in controlling excitability in a number of systems, such as regulation of the contraction of smooth muscle, the tuning of hair cells in the cochlea, regulation of transmitter release, and innate immunity. In smooth muscles, its activation by high level of Ca(2+), caused by ryanodine receptors in the sarcoplasmic reticulum, regulates the membrane potential. In cochlea cells, its number and kinetic properties partly determine the characteristic frequency of each hair cell and thereby helps to establish a tonotopic map. Kinetics of KCNMA1 channels are determined by alternative splicing, phosphorylation status and its combination with modulating beta subunits. Highly sensitive to both iberiotoxin (IbTx) and charybdotoxin (CTX).</specific-function>
        <gene-name>KCNMA1</gene-name>
        <locus>10q22.3</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>87-107
179-199
215-235
240-260
265-285
301-321
368-388</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>7.07</theoretical-pi>
        <molecular-weight>137558.115</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:6284</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>KCNMA1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U13913</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>537439</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>380</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>380</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q12791</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>KCMA1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>BK channel</synonym>
          <synonym>BKCA alpha</synonym>
          <synonym>Calcium-activated potassium channel, subfamily M subunit alpha-1</synonym>
          <synonym>hSlo</synonym>
          <synonym>K(VCA)alpha</synonym>
          <synonym>KCa1.1</synonym>
          <synonym>KCNMA</synonym>
          <synonym>Maxi K channel</synonym>
          <synonym>MaxiK</synonym>
          <synonym>SLO</synonym>
          <synonym>Slo homolog</synonym>
          <synonym>Slo-alpha</synonym>
          <synonym>Slo1</synonym>
          <synonym>Slowpoke homolog</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001104|Calcium-activated potassium channel subunit alpha-1
MANGGGGGGGSSGGGGGGGGSSLRMSSNIHANHLSLDASSSSSSSSSSSSSSSSSSSSSS
VHEPKMDALIIPVTMEVPCDSRGQRMWWAFLASSMVTFFGGLFIILLWRTLKYLWTVCCH
CGGKTKEAQKINNGSSQADGTLKPVDEKEEAVAAEVGWMTSVKDWAGVMISAQTLTGRVL
VVLVFALSIGALVIYFIDSSNPIESCQNFYKDFTLQIDMAFNVFFLLYFGLRFIAANDKL
WFWLEVNSVVDFFTVPPVFVSVYLNRSWLGLRFLRALRLIQFSEILQFLNILKTSNSIKL
VNLLSIFISTWLTAAGFIHLVENSGDPWENFQNNQALTYWECVYLLMVTMSTVGYGDVYA
KTTLGRLFMVFFILGGLAMFASYVPEIIELIGNRKKYGGSYSAVSGRKHIVVCGHITLES
VSNFLKDFLHKDRDDVNVEIVFLHNISPNLELEALFKRHFTQVEFYQGSVLNPHDLARVK
IESADACLILANKYCADPDAEDASNIMRVISIKNYHPKIRIITQMLQYHNKAHLLNIPSW
NWKEGDDAICLAELKLGFIAQSCLAQGLSTMLANLFSMRSFIKIEEDTWQKYYLEGVSNE
MYTEYLSSAFVGLSFPTVCELCFVKLKLLMIAIEYKSANRESRILINPGNHLKIQEGTLG
FFIASDAKEVKRAFFYCKACHDDITDPKRIKKCGCKRPKMSIYKRMRRACCFDCGRSERD
CSCMSGRVRGNVDTLERAFPLSSVSVNDCSTSFRAFEDEQPSTLSPKKKQRNGGMRNSPN
TSPKLMRHDPLLIPGNDQIDNMDSNVKKYDSTGMFHWCAPKEIEKVILTRSEAAMTVLSG
HVVVCIFGDVSSALIGLRNLVMPLRASNFHYHELKHIVFVGSIEYLKREWETLHNFPKVS
ILPGTPLSRADLRAVNINLCDMCVILSANQNNIDDTSLQDKECILASLNIKSMQFDDSIG
VLQANSQGFTPPGMDRSSPDNSPVHGMLRQPSITTGVNIPIITELVNDTNVQFLDQDDDD
DPDTELYLTQPFACGTAFAVSVLDSLMSATYFNDNILTLIRTLVTGGATPELEALIAEEN
ALRGGYSTPQTLANRDRCRVAQLALLDGPFADLGDGGCYGDLFCKALKTYNMLCFGIYRL
RDAHLSTPSQCTKRYVITNPPYEFELVPTDLIFCLMQFDHNAGQSRASLSHSSHSSQSSS
KKSSSVHSIPSTANRQNRPKSRESRDKQKYVQEERL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021262|Calcium-activated potassium channel subunit alpha-1 (KCNMA1)
ATGGCAAATGGTGGCGGCGGCGGCGGCGGCAGCAGCGGCGGCGGCGGCGGCGGCGGAGGC
AGCAGTCTTAGAATGAGTAGCAATATCCACGCGAACCATCTCAGCCTAGACGCGTCCTCC
TCCTCCTCCTCCTCCTCTTCCTCTTCTTCTTCTTCCTCCTCCTCTTCCTCCTCGTCCTCG
GTCCACGAGCCCAAGATGGATGCGCTCATCATCCCGGTGACCATGGAGGTGCCGTGCGAC
AGCCGGGGCCAACGCATGTGGTGGGCTTTCCTGGCCTCCTCCATGGTGACTTTCTTCGGG
GGCCTCTTCATCATCTTGCTCTGGCGGACGCTCAAGTACCTGTGGACCGTGTGCTGCCAC
TGCGGGGGCAAGACGAAGGAGGCCCAGAAGATTAACAATGGCTCAAGCCAGGCGGATGGC
ACTCTCAAACCAGTGGATGAAAAAGAGGAGGCAGTGGCCGCCGAGGTCGGCTGGATGACC
TCCGTGAAGGACTGGGCGGGGGTGATGATATCCGCCCAGACACTGACTGGCAGAGTCCTG
GTTGTCTTAGTCTTTGCTCTCAGCATCGGTGCACTTGTAATATACTTCATAGATTCATCA
AACCCAATAGAATCCTGCCAGAATTTCTACAAAGATTTCACATTACAGATCGACATGGCT
TTCAACGTGTTCTTCCTTCTCTACTTCGGCTTGCGGTTTATTGCAGCCAACGATAAATTG
TGGTTCTGGCTGGAAGTGAACTCTGTAGTGGATTTCTTCACGGTGCCCCCCGTGTTTGTG
TCTGTGTACTTAAACAGAAGTTGGCTTGGTTTGAGATTTTTAAGAGCTCTGAGACTGATA
CAGTTTTCAGAAATTTTGCAGTTTCTGAATATTCTTAAAACAAGTAATTCCATCAAGCTG
GTGAATCTGCTCTCCATATTTATCAGCACGTGGCTGACTGCAGCCGGGTTCATCCATTTG
GTGGAGAATTCAGGGGACCCATGGGAAAATTTCCAAAACAACCAGGCTCTCACCTACTGG
GAATGTGTCTATTTACTCATGGTCACAATGTCCACCGTTGGTTATGGGGATGTTTATGCA
AAAACCACACTTGGGCGCCTCTTCATGGTCTTCTTCATCCTCGGGGGACTGGCCATGTTT
GCCAGCTACGTCCCTGAAATCATAGAGTTAATAGGAAACCGCAAGAAATACGGGGGCTCC
TATAGTGCGGTTAGTGGAAGAAAGCACATTGTGGTCTGCGGACACATCACTCTGGAGAGT
GTTTCCAACTTCCTGAAGGACTTTCTGCACAAGGACCGGGATGACGTCAATGTGGAGATC
GTTTTTCTTCACAACATCTCCCCCAACCTGGAGCTTGAAGCTCTGTTCAAACGACATTTT
ACTCAGGTGGAATTTTATCAGGGTTCCGTCCTCAATCCACATGATCTTGCAAGAGTCAAG
ATAGAGTCAGCAGATGCATGCCTGATCCTTGCCAACAAGTACTGCGCTGACCCGGATGCG
GAGGATGCCTCGAATATCATGAGAGTAATCTCCATAAAGAACTACCATCCGAAGATAAGA
ATCATCACTCAAATGCTGCAGTATCACAACAAGGCCCATCTGCTAAACATCCCGAGCTGG
AATTGGAAAGAAGGTGATGACGCAATCTGCCTCGCAGAGTTGAAGTTGGGCTTCATAGCC
CAGAGCTGCCTGGCTCAAGGCCTCTCCACCATGCTTGCCAACCTCTTCTCCATGAGGTCA
TTCATAAAGATTGAGGAAGACACATGGCAGAAATACTACTTGGAAGGAGTCTCAAATGAA
ATGTACACAGAATATCTCTCCAGTGCCTTCGTGGGTCTGTCCTTCCCTACTGTTTGTGAG
CTGTGTTTTGTGAAGCTCAAGCTCCTAATGATAGCCATTGAGTACAAGTCTGCCAACCGA
GAGAGCCGAAGCCGAAAGCGTATATTAATTAATCCTGGAAACCATCTTAAGATCCAAGAA
GGTACTTTAGGATTTTTCATCGCAAGTGATGCCAAAGAAGTTAAAAGGGCATTTTTTTAC
TGCAAGGCCTGTCATGATGACATCACAGATCCCAAAAGAATAAAAAAATGTGGCTGCAAA
CGGCTTGAAGATGAGCAGCCGTCAACACTATCACCAAAAAAAAAGCAACGGAATGGAGGC
ATGCGGAACTCACCCAACACCTCGCCTAAGCTGATGAGGCATGACCCCTTGTTAATTCCT
GGCAATGATCAGATTGACAACATGGACTCCAATGTGAAGAAGTACGACTCTACTGGGATG
TTTCACTGGTGTGCACCCAAGGAGATAGAGAAAGTCATCCTGACTCGAAGTGAAGCTGCC
ATGACCGTCCTGAGTGGCCATGTCGTGGTCTGCATCTTTGGCGACGTCAGCTCAGCCCTG
ATCGGCCTCCGGAACCTGGTGATGCCGCTCCGTGCCAGCAACTTTCATTACCATGAGCTC
AAGCACATTGTGTTTGTGGGCTCTATTGAGTACCTCAAGCGGGAATGGGAGACGCTTCAT
AACTTCCCCAAAGTGTCCATATTGCCTGGTACGCCATTAAGTCGGGCTGATTTAAGGGCT
GTCAACATCAACCTCTGTGACATGTGCGTTATCCTGTCAGCCAATCAGAATAATATTGAT
GATACTTCGCTGCAGGACAAGGAATGCATCTTGGCGTCACTCAACATCAAATCTATGCAG
TTTGATGACAGCATCGGAGTCTTGCAGGCTAATTCCCAAGGGTTCACACCTCCAGGAATG
GATAGATCCTCTCCAGATAACAGCCCAGTGCACGGGATGTTACGTCAACCATCCATCACA
ACTGGGGTCAACATCCCCATCATCACTGAACTAGTGAACGATACTAATGTTCAGTTTTTG
GACCAAGACGATGATGATGACCCTGATACAGAACTGTACCTCACGCAGCCCTTTGCCTGT
GGGACAGCATTTGCCGTCAGTGTCCTGGACTCACTCATGAGCGCGACGTACTTCAATGAC
AATATCCTCACCCTGATACGGACCCTGGTGACCGGAGGAGCCACGCCGGAGCTGGAGGCT
CTGATTGCTGAGGAAAACGCCCTTAGAGGTGGCTACAGCACCCCGCAGACACTGGCCAAT
AGGGACCGCTGCCGCGTGGCCCAGTTAGCTCTGCTCGATGGGCCATTTGCGGACTTAGGG
GATGGTGGTTGTTATGGTGATCTGTTCTGCAAAGCTCTGAAAACATATAATATGCTTTGT
TTTGGAATTTACCGGCTGAGAGATGCTCACCTCAGCACCCCCAGTCAGTGCACAAAGAGG
TATGTCATCACCAACCCGCCCTATGAGTTTGAGCTCGTGCCGACGGACCTGATCTTCTGC
TTAATGCAGTTTGACCACAATGCCGGCCAGTCCCGGGCCAGCCTGTCCCATTCCTCCCAC
TCGTCGCAGTCCTCCAGCAAGAAGAGCTCCTCTGTTCACTCCATCCCATCCACAGCAAAC
CGACAGAACCGGCCCAAGTCCAGGGAGTCCCGGGACAAACAGAACAGAAAAGAAATGGTT
TACAGATGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00520</identifier>
            <name>Ion_trans</name>
          </pfam>
          <pfam>
            <identifier>PF03493</identifier>
            <name>BK_channel_a</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>caveola</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>external side of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>terminal bouton</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated potassium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>actin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium-activated potassium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>large conductance calcium-activated potassium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated potassium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adult walking behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>auditory receptor cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell maturation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular potassium ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>eye blink reflex</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>locomotor rhythm</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>micturition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell volume</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuromuscular process controlling balance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuronal action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>potassium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>potassium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein homooligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of aldosterone metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>relaxation of vascular smooth muscle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to calcium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to carbon monoxide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to osmotic stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>saliva secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of sound</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>smooth muscle contraction involved in micturition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>